Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
CMTA Adds Science Writer Kenneth Raymond to Team
…for patients and their families. The CMTA has invested $23.5 million in the search for a cure and its Strategy to Accelerate Research (STAR) brings world-renowned CMT researchers together with…
CMTA Lunch & Learn: Neuro-Toxic Medication List Update
07/13/2023 @ 12:00 pm – 1:00 pm – Please join us on July 13 at 12:00 p.m. Eastern Time to hear an update on the newly reviewed and revised CMT Neuro-toxic Medication List. The CMTA funded a grant awarded to Guido Cavaletti, MD at the University of Milano-Bicocca to review and update the current CMT neuro-toxic medication list. Dr. Cavaletti and colleague, Dr. […]
CMTA to attend the annual BIO partnering conference in Boston
The CMTA is a global leader in the acceleration of CMT research and pre-clinical testing. The CMTA will be attending the BIO annual meeting in Boston and have availability for…
Gifts of Stock
The CMTA is strongly committed to client services and to funding research and finding a cure. Gifts to client services make the day-to-day function of the CMTA possible, enabling us…
Types of CMT
…because, by nerve conduction characteristics, it is neither demyelinating nor axonal – it is somewhere in between – it is intermediate. Learn more about how CMTA is accelerating research for…
From Gene Discovery to Gene Editing: Closing the Diagnostic Gap and Developing CRISPR/Cas9 Capabilities in CMT
…with the Inherited Neuropathies Consortium (INC), researchers at the University of Miami, led by CMTA Strategy To Accelerate Research (STAR) Board member Stephan Zuchner, MD, PhD, are working to solve…
What is CMT?
…Accelerate Research (STAR) in 2008, CMTA has been working with preeminent researchers, clinicians, patients and institutions in the global inherited neuropathy community to capitalize on breakthroughs in genetics. Unlike other…